Exhibit 99

USANA Adds Additional $40 Million to Authorized Share Repurchase Program

    SALT LAKE CITY--(BUSINESS WIRE)--April 10, 2007--USANA Health
Sciences, Inc. (NASDAQ: USNA) ("USANA" or "the Company") today
announced that its board of directors has authorized an additional $40
million for share repurchases of its outstanding common stock.

    Repurchases may be made from time to time, in the open market,
through block trades or otherwise. The number of shares to be
purchased and the timing of purchases will be based on market
conditions, the level of cash balances, general business
opportunities, and other factors.

    "The Board has authorized additional funding for our stock
repurchase program, which illustrates our confidence in our future
growth potential," said Dave Wentz, president of USANA. "We will
continue to explore opportunities to build long-term value for all of
our stakeholders."

    Today's $40 million authorization will be in addition to the
approximately $25 million currently available. During 2006, the
Company repurchased about one million shares for a total investment of
nearly $41 million.

    About USANA

    USANA develops and manufactures high quality nutritional and
personal care products that are sold directly to Associates and
Preferred Customers throughout the United States, Canada, Australia,
New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico,
the Netherlands, and the United Kingdom. More information on USANA can
be found at http://www.usanahealthsciences.com.

    Safe Harbor

    This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Actual results could differ materially from
those projected in these forward-looking statements, which involve a
number of risks and uncertainties, including reliance upon our network
of independent Associates, the governmental regulation of our
products, manufacturing and marketing risks, and uncertainties
associated with our planned international expansion. The contents of
this release should be considered in conjunction with the risk
factors, warnings, and cautionary statements that are contained in our
most recent filings with the Securities and Exchange Commission.

    CONTACT: USANA Health Sciences, Inc.
             Riley Timmer, 801-954-7100 (Investor Relations)
             investor.relations@us.usana.com
             or
             Edelman
             Joe Poulos, 312-240-2719 (Media)